接受palbociclib和abemaciclib的患者的不良事件概况之间的比较:对两个真实世界的数据库进行分析
Tatsuaki Takeda1,2, Shiho Sugimoto3, Jun Matsumoto4,5,6
1Department of Education and Research Center for Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.
作为乳腺癌的CDK4/6抑制剂的Palbociclib和abemaciclib显示出不同的不良事件概况. 帕尔博西克利布与细胞衰减和神经系统问题有关,而阿贝马西克利布与肺部疾病和脏疾病有关.
科学领域:
- 在瘤学瘤学.
- 药物监督 药物监督 药物监督
- 临床药理学 临床药理学
背景情况:
- 帕尔博西克利布和阿贝马西克利布是用于乳腺癌治疗的CDK4/6抑制剂.
- 虽然在治疗上是相似的,但它们的独特不良事件 (AE) 概况尚未明确定义.
研究的目的:
- 为了比较palbociclib和abemaciclib的现实世界AE概况.
- 为了确定这两种CDK4/6抑制剂之间的特定安全差异.
主要方法:
- 使用了两个大型现实世界数据库:VigiBase和FAERS.
- 分析了2022年12月之前用palbociclib或abemaciclib治疗的乳腺癌患者的数据.
- 在200种类型的AE中使用不成比例分析 (报告赔率比率).
主要成果:
- 帕尔博西克利布的使用与频繁的细胞衰竭和精神病/神经系统疾病有关.
- 使用abemaciclib显示间歇性肺病,腹和脏/尿路疾病的频率更高.
- 两种CDK4/6抑制剂之间的AE概况存在显著差异.
结论:
- 这项研究提供了对palbociclib和abemaciclib不良事件概况的全面比较.
- 研究结果强调需要考虑药物特定的AE概况,以获得乳腺癌治疗中最佳患者结果.
- 对CDK4/6抑制剂的知情选择可以提高患者的安全性和治疗疗效.
更多相关视频
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
相关概念视频
Comparing the Survival Analysis of Two or More Groups
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Inhibition of Cdk Activity
Hazard Ratio
For example, in a clinical trial...
Kaplan-Meier Approach
